Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.

Liver X receptor (LXR) activation improves glucose homeostasis in obesity. This improvement, however, is associated with several side effects including hyperlipidemia and hepatic steatosis. Activation of peroxisome proliferator-activated receptor alpha (PPARα), on the other hand, increases fatty aci...

Full description

Bibliographic Details
Main Authors: Mingming Gao, Le Bu, Yongjie Ma, Dexi Liu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3676322?pdf=render
_version_ 1828443394820538368
author Mingming Gao
Le Bu
Yongjie Ma
Dexi Liu
author_facet Mingming Gao
Le Bu
Yongjie Ma
Dexi Liu
author_sort Mingming Gao
collection DOAJ
description Liver X receptor (LXR) activation improves glucose homeostasis in obesity. This improvement, however, is associated with several side effects including hyperlipidemia and hepatic steatosis. Activation of peroxisome proliferator-activated receptor alpha (PPARα), on the other hand, increases fatty acid oxidation, leading to a reduction of hyperlipidemia. The objective of this study was to investigate whether concurrent activation of LXR/PPARα can produce synergistic benefits in treating obesity-associated metabolic disorders. Treatment of high fat diet-induced obese mice with T0901317, an LXR activator, or fenofibrate, the PPARα agonist, or in combination alleviated insulin resistance and improved glucose tolerance. The combined treatment dramatically exacerbated hepatic steatosis. Gene expression analysis in the liver showed that combined treatment increased the expression of genes involved in lipogenesis and fatty acid transport, including srebp-1c, chrebp, acc1, fas, scd1 and cd36. Histochemistry and ex vivo glycerol releasing assay showed that combined treatment accelerated lipid mobilization in adipose tissue. Combined treatment also increased the transcription of glut4, hsl, atgl and adiponectin, and decreased that of plin1, cd11c, ifnγ and leptin. Combined treatment markedly elevated the transcription of fgf21 in liver but not in adipose tissue. These results suggest that concurrent activation of LXR and PPARα as a strategy to control glucose and lipid metabolism in obesity is beneficial but could lead to elevation of lipid accumulation in the liver.
first_indexed 2024-12-10T21:28:38Z
format Article
id doaj.art-ff8c96b994604b9c8737aa64d24c982e
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-10T21:28:38Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-ff8c96b994604b9c8737aa64d24c982e2022-12-22T01:32:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6564110.1371/journal.pone.0065641Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.Mingming GaoLe BuYongjie MaDexi LiuLiver X receptor (LXR) activation improves glucose homeostasis in obesity. This improvement, however, is associated with several side effects including hyperlipidemia and hepatic steatosis. Activation of peroxisome proliferator-activated receptor alpha (PPARα), on the other hand, increases fatty acid oxidation, leading to a reduction of hyperlipidemia. The objective of this study was to investigate whether concurrent activation of LXR/PPARα can produce synergistic benefits in treating obesity-associated metabolic disorders. Treatment of high fat diet-induced obese mice with T0901317, an LXR activator, or fenofibrate, the PPARα agonist, or in combination alleviated insulin resistance and improved glucose tolerance. The combined treatment dramatically exacerbated hepatic steatosis. Gene expression analysis in the liver showed that combined treatment increased the expression of genes involved in lipogenesis and fatty acid transport, including srebp-1c, chrebp, acc1, fas, scd1 and cd36. Histochemistry and ex vivo glycerol releasing assay showed that combined treatment accelerated lipid mobilization in adipose tissue. Combined treatment also increased the transcription of glut4, hsl, atgl and adiponectin, and decreased that of plin1, cd11c, ifnγ and leptin. Combined treatment markedly elevated the transcription of fgf21 in liver but not in adipose tissue. These results suggest that concurrent activation of LXR and PPARα as a strategy to control glucose and lipid metabolism in obesity is beneficial but could lead to elevation of lipid accumulation in the liver.http://europepmc.org/articles/PMC3676322?pdf=render
spellingShingle Mingming Gao
Le Bu
Yongjie Ma
Dexi Liu
Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
PLoS ONE
title Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
title_full Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
title_fullStr Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
title_full_unstemmed Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
title_short Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
title_sort concurrent activation of liver x receptor and peroxisome proliferator activated receptor alpha exacerbates hepatic steatosis in high fat diet induced obese mice
url http://europepmc.org/articles/PMC3676322?pdf=render
work_keys_str_mv AT mingminggao concurrentactivationofliverxreceptorandperoxisomeproliferatoractivatedreceptoralphaexacerbateshepaticsteatosisinhighfatdietinducedobesemice
AT lebu concurrentactivationofliverxreceptorandperoxisomeproliferatoractivatedreceptoralphaexacerbateshepaticsteatosisinhighfatdietinducedobesemice
AT yongjiema concurrentactivationofliverxreceptorandperoxisomeproliferatoractivatedreceptoralphaexacerbateshepaticsteatosisinhighfatdietinducedobesemice
AT dexiliu concurrentactivationofliverxreceptorandperoxisomeproliferatoractivatedreceptoralphaexacerbateshepaticsteatosisinhighfatdietinducedobesemice